贝伐单抗联合PB方案治疗中晚期宫颈癌的临床观察

目的观察贝伐单抗联合PB方案治疗中晚期宫颈癌疗效。方法选32例中晚期宫颈癌患者，分为两组，单纯组：PB方案：DDP50mg／m^2，静脉滴注，第1、2天；BLM30mg／m^2，静脉滴注，第2天。每三周重复共3疗程。联合组：在PB方案用药的间歇期加用贝伐单抗5mg／kg，每1周静脉注射一次。3个疗程后评价疗效。结果3个疗程后联合组：有效率87．5％（14／16）；单纯组：有效率75％（12／16）。联合治疗组显著高于单纯组。联合组的生活质量、重新获得手术机会的比例均优于单纯组。结论贝伐单抗联合PB方案治疗中晚期宫颈癌，可提高疗效，使部分失去手术机会的中晚期宫颈癌患者重新获得手术机会。

Clinical Curative Effect of Bevacizumab Combined PB Project to Treat Cervical Carcinoma in Middle and Late Stage

To observe the efficacy of bevacizumab combined with PB project in treatment of cervica carcinoma in middle and late stage. Methods 32 cases with cervical carcinoma in middle and late stage were randomly divided into simple group and united group. The former were treated with PB project, DDP 50mg/m^2, by intravenous drip on the first two treating days, BLM 30mg/ m^2, by intravenous drip on the second treating day. Three weeks for a treatment course, a total of three courses were needed. For the later, Bevacizumab was used among the intervals of PB project medication, at a dose of 5mg/kg, by intravenous dirp, for once every two weeks. After three treatment courses, the curative effect was evaluated. Results For the united group, the efficient was 87.5%（14/16h for the simple group, the efficient was 75%（12/16）. The efficient for the united group was significantly higher than that of simple group. The life quality, the proportaion of regaining the surgery opportunities of the united group are all superior to those of the simple group. Conclusion Bevacizumab combined PB project has a better effect on cervical carcinoma in middle and late stage. In this way, the efficacy can be improved so that the patients with carvical carcinoma in these periods who have lost the surgery opportunies can regain surgery chances.